<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "pembrolizumab inj VIAL>
<dose><value>2</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drug><value>pembrolizumab inj VIAL</value>
</drug><strength><value>50 mg</value>
</strength><frequency><value>EVERY 3 WEEKS</value>
</frequency><instruction><value>Administer dose diluted on 50 mL sodium chloride 0.9% over 30 minutes.</value>
</instruction><volume><value></value>
</volume><units><value>mg/kg</value>
</units><additionalnotes><value>There are no dose reductions for pembrolizumab. Doses are either delayed or discontinued for toxicity.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=8661</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>